Malin Corporation | MLC - Operating Expenses


Malin Corporation reported EUR1.1M in Operating Expenses for its fiscal semester ending in December of 2024.





Operating Expenses Change Date
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alaunos Therapeutics USD 1.01M 175K Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Avita Medical AUD 28.02M 1.55M Dec/2025
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Eurofins Scientific SE EUR 3.29B 462.3M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
IQVIA Holdings USD 6.22B 4.53B Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 1.78B 242M Mar/2026
Organon & Co USD 903M 387M Mar/2026
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Revvity USD 628.34M 2.12M Mar/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Viatris USD 3.54B 323.9M Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026